Skip to content

Non-invasive Staging and Evaluation Model of Chronic Kidney Disease Based on Multi-site Photoplethysmography (PPG) Features.

Non-invasive Staging and Evaluation Model of Chronic Kidney Disease Based on Multi-site Photoplethysmography (PPG) Features.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125235
Enrollment
Unknown
Registered
2026-05-22
Start date
2026-05-22
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

CKD3:None
CKD1:None
CKD4:None
CKD5:NONE
CKD2:None
H:None

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age > 18 years; 2. An ECG showing sinus rhythm within the past 3 months or at screening, with a resting heart rate within the relatively normal range (60–100 beats per minute); 3. Subjects meeting any of the following criteria: (1) Healthy group: Healthy volunteers with no abnormalities observed in urine analysis or urinary tract ultrasound. (2) Stage 1: Participants diagnosed with CKD and with an eGFR >= 90 mL/min/1.73 m^2. (3) Stage 2: Participants diagnosed with CKD and with an eGFR between 60 and 89 mL/min/1.73 m^2. (4) Stage 3: Participants diagnosed with CKD and with an eGFR of 30 <= eGFR <= 59 mL/min/1.73 m^2. (5) Stage 4: Participants diagnosed with CKD and with an eGFR of 15 <= eGFR <= 30 mL/min/1.73 m^2. (6) Stage 5: Diagnosed with CKD, and eGFR < 15 mL/min/1.73 m^2. 4. Voluntarily participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with an implanted permanent pacemaker; 2.Severe arrhythmias (atrial fibrillation, atrial flutter, second-degree or higher atrioventricular block, frequent premature beats > 5 per minute); 3.Acute kidney injury (AKI) within 3 months prior to enrolment, or marked fluctuations in renal function (a relative decline in eGFR of >20% from baseline within the past 3 months); 4.Tremor or amputation of the upper or lower limbs, or severe skin disease; 5.Severe heart failure (NYHA Class III–IV); 6.Severe infection, advanced cancer, or severe physical or mental illness rendering the patient unable to tolerate or cooperate with the study; 7.Patients who have undergone haemodialysis, peritoneal dialysis, or kidney transplantation; 8.Known pregnancy.

Design outcomes

Primary

MeasureTime frame
Scr;

Secondary

MeasureTime frame
Age, gender, height, weight, BMI, etc.;

Countries

China

Contacts

Public ContactChen Limeng

Peking Union Medical College Hospital

chenlpumch@163.com+86 10 6915 5057

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026